Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
Trial details
- Registry ID
- NCT05352893
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as ANB019
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPPNCT05352893 | Vanda Pharmaceuticals | Phase 3 | Completed | 2023-08-17Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |